Biomarkers in HER2-Negative EBC

CE / CME

Overview of Risk Assessment and Biomarker Testing to Inform Treatment in HER2-Negative Early Breast Cancer

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Nurses: 0.50 Nursing contact hour

Released: April 06, 2022

Expiration: April 05, 2023

Activity

Progress
1
Course Completed

In this module, Yara Abdou, MD, discusses new guideline recommendations on risk assessment tools and biomarker testing that inform patient prognosis and predict treatment response in patients with early breast cancer (EBC).

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with breast cancer do you provide care for in a typical month?

You are treating a 46-year-old woman who presented with a 6-cm left breast mass with multiple clinically palpable lymph nodes. Core biopsy confirms invasive ductal carcinoma, estrogen receptor (ER) positive, progesterone receptor (PR) positive, and HER2 negative. Ki-67 score was 60%. Germline mutation testing confirms no pathogenic variants. She plans to undergo neoadjuvant chemotherapy followed by surgery.

Which of the following characterizes her best adjuvant treatment option based on recent data?